Download PDFPDF

Aerobic performance among healthy (non-asthmatic) adults using beta2-agonists: a systematic review and meta-analysis of randomised controlled trials
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    The effects of beta 2 agonists on aerobic performance in healthy adults – implications for PED rules
    • Conor P O'Brien, Medical Consultant Blackrock Clinic Dublin.Former Chairperson of the Irish Anti-Doping Comitteee, .Former WADA TUE committee member

    Dear Sir/Madam
    Riiser’s et al paper outlines the long-held belief that beta 2 agonists do not improve aerobic function in a healthy population. Beta 2 agonist however have other performance enhancing affects. Clenbuterol, the beta 2 agonist is a case in point. This drug has been used by athletes for decades to burn fat, through metabolic up regulation. This beta 2 agonist drug is also suggested to improved muscle growth through its effects on protein synthesis. It is hypostasised that Clenbuterol induces phosphorylation of mTOR which resulting in enhanced muscle protein synthesis.
    Drugs are banned in sport based on the presence of 2 of 3 criteria: 1) Performance enhancing. 2) Dangerous to health 3) Against the ethos of sport.
    While Beta 2 agonist may not improve aerobic function, they can be performance enhancing. They also carry significant side effects in unsupervised hands. The ethos of sport is perhaps a moot point.
    Anti-Doping began in earnest in 1967 following the death of a number of athletes. Participant’s health and safety has been the cardinal element in all programs for the past 54 years. The TUE element ensures that every athlete, whatever the medical condition can participate without discrimination, once the disease has been confirmed. If a Beta 2 agent is medically required then an appropriate agent will be approved by the local governing TUE body, and safe participation can follow. Anti- Doping in a complex area and non – binary. A f...

    Show More
    Conflict of Interest:
    None declared.